JP2009526756A - Ｉｌ−３１ｒａアンタゴニストおよびｏｓｍｒｂアンタゴニストを用いて神経組織における疼痛および炎症を治療する方法 - Google Patents

Ｉｌ−３１ｒａアンタゴニストおよびｏｓｍｒｂアンタゴニストを用いて神経組織における疼痛および炎症を治療する方法 Download PDF

Info

Publication number
JP2009526756A
JP2009526756A JP2008550490A JP2008550490A JP2009526756A JP 2009526756 A JP2009526756 A JP 2009526756A JP 2008550490 A JP2008550490 A JP 2008550490A JP 2008550490 A JP2008550490 A JP 2008550490A JP 2009526756 A JP2009526756 A JP 2009526756A
Authority
JP
Japan
Prior art keywords
antagonist
antibody
pain
osmrb
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008550490A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009526756A5 (enExample
Inventor
ユエ ヤオ
ジャニーン ビルスバーロウ
セシール クレスジャ
リンダ ズッカーマン
マーク ローゲ
Original Assignee
ザイモジェネティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザイモジェネティクス， インコーポレイテッド filed Critical ザイモジェネティクス， インコーポレイテッド
Publication of JP2009526756A publication Critical patent/JP2009526756A/ja
Publication of JP2009526756A5 publication Critical patent/JP2009526756A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008550490A 2006-01-10 2007-01-10 Ｉｌ−３１ｒａアンタゴニストおよびｏｓｍｒｂアンタゴニストを用いて神経組織における疼痛および炎症を治療する方法 Pending JP2009526756A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US75806606P 2006-01-10 2006-01-10
US75797906P 2006-01-10 2006-01-10
US77303106P 2006-02-14 2006-02-14
US80555206P 2006-06-22 2006-06-22
US80555006P 2006-06-22 2006-06-22
US80555406P 2006-06-22 2006-06-22
US82398706P 2006-08-30 2006-08-30
US82398206P 2006-08-30 2006-08-30
PCT/US2007/060337 WO2007133816A2 (en) 2006-01-10 2007-01-10 Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists

Publications (2)

Publication Number Publication Date
JP2009526756A true JP2009526756A (ja) 2009-07-23
JP2009526756A5 JP2009526756A5 (enExample) 2010-02-25

Family

ID=38694567

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008550490A Pending JP2009526756A (ja) 2006-01-10 2007-01-10 Ｉｌ−３１ｒａアンタゴニストおよびｏｓｍｒｂアンタゴニストを用いて神経組織における疼痛および炎症を治療する方法
JP2008550488A Pending JP2009528264A (ja) 2006-01-10 2007-01-10 Ｉｌ−３１アンタゴニストを用いて神経組織における疼痛及び炎症を治療する方法
JP2012240592A Pending JP2013047259A (ja) 2006-01-10 2012-10-31 Ｉｌ−３１アンタゴニストを用いて神経組織における疼痛及び炎症を治療する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2008550488A Pending JP2009528264A (ja) 2006-01-10 2007-01-10 Ｉｌ−３１アンタゴニストを用いて神経組織における疼痛及び炎症を治療する方法
JP2012240592A Pending JP2013047259A (ja) 2006-01-10 2012-10-31 Ｉｌ−３１アンタゴニストを用いて神経組織における疼痛及び炎症を治療する方法

Country Status (11)

Country Link
US (22) US7514077B2 (enExample)
EP (4) EP2001906A2 (enExample)
JP (3) JP2009526756A (enExample)
KR (1) KR101345586B1 (enExample)
AU (2) AU2007254715B2 (enExample)
BR (1) BRPI0706487A2 (enExample)
CA (2) CA2636288C (enExample)
IL (4) IL192130A0 (enExample)
MX (1) MX2008008831A (enExample)
RU (1) RU2565391C2 (enExample)
WO (2) WO2007143231A2 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016522164A (ja) * 2013-03-27 2016-07-28 セダーズ−シナイ メディカル センター Ｔｌ１ａ機能および関連するシグナル経路の抑制による線維症および炎症の緩和および回復
WO2017033951A1 (ja) * 2015-08-24 2017-03-02 学校法人国際医療福祉大学 新規鎮痛剤
JP2017140056A (ja) * 2013-05-30 2017-08-17 キニクサ ファーマシューティカルズ， リミテッド オンコスタチンｍ受容体抗原結合タンパク質
JP2018506528A (ja) * 2015-01-29 2018-03-08 オックスフォード ユニヴァーシティ イノヴェーション リミテッド Ｉｂｄにおける治療標的及びバイオマーカー
US10316083B2 (en) 2013-07-19 2019-06-11 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
US11186872B2 (en) 2016-03-17 2021-11-30 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through RNASET2
US11236393B2 (en) 2008-11-26 2022-02-01 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-TNFα therapy in inflammatory bowel disease

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2325316B8 (en) 1999-06-02 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, NR10
DE60025241T2 (de) 1999-09-27 2007-01-11 Chugai Seiyaku K.K. HäMOPOIETINREZEPTOR-PROTEIN, NR12
ATE401390T1 (de) * 2002-01-18 2008-08-15 Zymogenetics Inc Zytokin (zcytor17-ligand)
CA2594490A1 (en) 2005-02-14 2006-08-24 Zymogenetics Inc. Methods of treating skin disorders using an il-31ra antagonist
EP1856150A2 (en) 2005-02-14 2007-11-21 ZymoGenetics, Inc. Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
KR101446989B1 (ko) * 2005-05-06 2014-10-15 지모제넥틱스, 인코포레이티드 Ｉｌ-31 단클론성 항체 및 사용법
US20130216542A1 (en) 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
CA2636288C (en) * 2006-01-10 2015-02-24 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists
IN2014DN10515A (enExample) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
CL2007001665A1 (es) 2006-06-08 2008-01-18 Chugai Pharmaceutical Co Ltd Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria.
RU2009111884A (ru) * 2006-09-01 2010-10-10 Займоджинетикс, Инк. (Us) Последовательности вариабельных областей моноклональных антител против il-31 и способы использования
EP2061496A2 (en) * 2007-01-10 2009-05-27 Zymogenetics, Inc. Methods of using il-31 to treat airway hyper-responsiveness and asthma
MX336725B (es) 2007-09-26 2016-01-28 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
DK3059246T3 (en) * 2007-09-26 2018-10-01 Chugai Pharmaceutical Co Ltd Modified constant region of an antibody
MY185647A (en) 2007-12-05 2021-05-27 Chugai Pharmaceutical Co Ltd Therapeutic agent for pruritus
BRPI0821110B8 (pt) 2007-12-05 2021-05-25 Chugai Pharmaceutical Co Ltd anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
LT2796466T (lt) 2007-12-07 2018-02-26 Zymogenetics, Inc. Humanizuotų antikūnų molekulės, specifinės il-31 atžvilgiu
TWI700293B (zh) 2008-04-11 2020-08-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗體
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
EP2348128A1 (en) * 2010-01-21 2011-07-27 Sanofi Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
KR102568454B1 (ko) 2010-11-30 2023-08-18 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8987289B2 (en) * 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US10039792B1 (en) 2013-03-16 2018-08-07 Brahm Holdings, Llc Methods for the treatment of inflammation and pain using human birth tissue material composition
MA43918A (fr) 2015-04-14 2018-12-05 Chugai Pharmaceutical Co Ltd Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
CA3003616C (en) * 2015-11-09 2020-07-28 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
CN110545844A (zh) 2017-02-21 2019-12-06 瑞美德生物医药科技有限公司 使用结合细胞毒性t淋巴细胞抗原-4(ctla-4)的抗体的癌症治疗
CN110546549B (zh) 2017-02-23 2022-06-07 奇跃公司 具有可变屈光力反射器的显示系统
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
WO2018190365A1 (ja) * 2017-04-12 2018-10-18 国立大学法人九州大学 神経障害性疼痛マーカー及びその使用
CA3093709C (en) 2018-03-16 2024-03-26 Zoetis Services Llc Peptide vaccines against interleukin-31
AU2019234220B2 (en) 2018-03-16 2025-09-11 Zoetis Services Llc Interleukin-31 monoclonal antibodies for veterinary use
MX2021000908A (es) 2018-07-23 2021-06-08 Trevi Therapeutics Inc Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.
RU2707954C1 (ru) * 2019-01-24 2019-12-02 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения онкологической боли
EP4062933A4 (en) 2019-11-20 2023-12-13 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
MX2022008554A (es) 2020-01-10 2022-08-10 Trevi Therapeutics Inc Metodos de administracion de nalbufina.
IL300694A (en) * 2020-09-01 2023-04-01 Chugai Pharmaceutical Co Ltd A pharmaceutical preparation for the prevention and/or treatment of dialysis pruritus that includes an IL-31 antagonist as an active ingredient
TW202304510A (zh) * 2021-04-07 2023-02-01 瑞士商葛德瑪控股公司 結節性癢疹之治療
WO2025226834A1 (en) * 2024-04-23 2025-10-30 Attovia Therapeutics, Inc. Il31-binding polypeptides and uses thereof
WO2026055142A1 (en) 2024-09-03 2026-03-12 Attovia Therapeutics, Inc. Il13 and il31 bispecific polypeptides and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004003140A2 (en) * 2002-01-18 2004-01-08 Zymogenetics, Inc. Cytokine receptor zcytor17 multimers
JP2005526494A (ja) * 2002-01-18 2005-09-08 ザイモジェネティクス，インコーポレイティド 新規サイトカインｚｃｙｔｏｒ１７リガンド

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US750795A (en) * 1904-02-02 Eugene j
US4054646A (en) * 1973-07-30 1977-10-18 General Electric Method and apparatus for detection of antibodies and antigens
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
US5492841A (en) * 1994-02-18 1996-02-20 E. I. Du Pont De Nemours And Company Quaternary ammonium immunogenic conjugates and immunoassay reagents
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
US5792850A (en) 1996-05-23 1998-08-11 Zymogenetics, Inc. Hematopoietic cytokine receptor
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
RU2175874C2 (ru) * 1999-03-17 2001-11-20 Борисов Виктор Александрович Способ лечения нарушений функций центральной нервной системы и устройство для его осуществления
EP2325316B8 (en) 1999-06-02 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, NR10
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1309620A2 (en) 2000-06-23 2003-05-14 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20030096339A1 (en) * 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
DK1325115T3 (en) * 2000-06-26 2016-11-21 Zymogenetics Inc CYTOKINRECEPTOR ZCYTOR17
JP2004514420A (ja) 2000-07-20 2004-05-20 ジェネンテック・インコーポレーテッド 分泌及び膜貫通ポリペプチドとそれをコードする核酸
CA2425169A1 (en) 2000-10-06 2002-04-11 Immunex Corporation Hematopoietin receptors hpr1 and hpr2
WO2002077230A1 (fr) 2001-03-26 2002-10-03 Chugai Seiyaku Kabushiki Kaisha Variants d'epissage nr10
EP2110434A1 (en) 2002-02-25 2009-10-21 Genentech, Inc. Type-1 cytokine receptor GLM-R
AU2006207945B2 (en) 2005-01-28 2012-02-09 Zymogenetics, Inc. Homogeneous preparations of IL-31
EP1856150A2 (en) 2005-02-14 2007-11-21 ZymoGenetics, Inc. Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
CA2594490A1 (en) 2005-02-14 2006-08-24 Zymogenetics Inc. Methods of treating skin disorders using an il-31ra antagonist
KR101446989B1 (ko) * 2005-05-06 2014-10-15 지모제넥틱스, 인코포레이티드 Ｉｌ-31 단클론성 항체 및 사용법
US8101183B2 (en) * 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
CA2636288C (en) 2006-01-10 2015-02-24 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists
RU2009111884A (ru) * 2006-09-01 2010-10-10 Займоджинетикс, Инк. (Us) Последовательности вариабельных областей моноклональных антител против il-31 и способы использования
EP2061496A2 (en) * 2007-01-10 2009-05-27 Zymogenetics, Inc. Methods of using il-31 to treat airway hyper-responsiveness and asthma
LT2796466T (lt) * 2007-12-07 2018-02-26 Zymogenetics, Inc. Humanizuotų antikūnų molekulės, specifinės il-31 atžvilgiu

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004003140A2 (en) * 2002-01-18 2004-01-08 Zymogenetics, Inc. Cytokine receptor zcytor17 multimers
JP2005526494A (ja) * 2002-01-18 2005-09-08 ザイモジェネティクス，インコーポレイティド 新規サイトカインｚｃｙｔｏｒ１７リガンド

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012019725; Ｅｕｒ．　Ｊ．　Ｐｈａｒｍａｃｏｌ．，　２００５，　Ｖｏｌ．５１６，　ｐｐ．１８０-１８１ *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11236393B2 (en) 2008-11-26 2022-02-01 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-TNFα therapy in inflammatory bowel disease
US12084722B2 (en) 2008-11-26 2024-09-10 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-TNFα therapy in inflammatory bowel disease
JP2022132362A (ja) * 2013-03-27 2022-09-08 セダーズ－シナイ メディカル センター Ｔｌ１ａ機能および関連するシグナル経路の抑制による線維症および炎症の緩和および回復
JP2016522164A (ja) * 2013-03-27 2016-07-28 セダーズ−シナイ メディカル センター Ｔｌ１ａ機能および関連するシグナル経路の抑制による線維症および炎症の緩和および回復
JP2020033379A (ja) * 2013-03-27 2020-03-05 セダーズ−シナイ メディカル センター Ｔｌ１ａ機能および関連するシグナル経路の抑制による線維症および炎症の緩和および回復
US10633449B2 (en) 2013-03-27 2020-04-28 Cedars-Sinai Medical Center Treatment and reversal of fibrosis and inflammation by inhibition of the TL1A-DR3 signaling pathway
US11434296B2 (en) 2013-03-27 2022-09-06 Cedars-Sinai Medical Center Mitigation and reversal of intestinal fibrosis and inflammation by inhibition of TL1A function
JP2017140056A (ja) * 2013-05-30 2017-08-17 キニクサ ファーマシューティカルズ， リミテッド オンコスタチンｍ受容体抗原結合タンパク質
US10316083B2 (en) 2013-07-19 2019-06-11 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
US11312768B2 (en) 2013-07-19 2022-04-26 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
US12269873B2 (en) 2013-07-19 2025-04-08 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
JP6999417B2 (ja) 2015-01-29 2022-02-04 オックスフォード ユニヴァーシティ イノヴェーション リミテッド Ｉｂｄにおける治療標的及びバイオマーカー
US10822406B2 (en) 2015-01-29 2020-11-03 Oxford University Innovation Limited Method for treating chronic intestinal inflammation and inflammatory bowel disease by administering antagonists of Oncostatin-M (OSM) and/or antagonists of OSM receptor-beta (OSMR)
JP2018506528A (ja) * 2015-01-29 2018-03-08 オックスフォード ユニヴァーシティ イノヴェーション リミテッド Ｉｂｄにおける治療標的及びバイオマーカー
WO2017033951A1 (ja) * 2015-08-24 2017-03-02 学校法人国際医療福祉大学 新規鎮痛剤
US11186872B2 (en) 2016-03-17 2021-11-30 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through RNASET2

Also Published As

Publication number Publication date
AU2007254715B2 (en) 2013-08-29
US20190112369A1 (en) 2019-04-18
US20180066050A1 (en) 2018-03-08
US8685395B2 (en) 2014-04-01
US7638126B2 (en) 2009-12-29
US20150132300A1 (en) 2015-05-14
US9334322B2 (en) 2016-05-10
EP1991581A2 (en) 2008-11-19
IL219677A0 (en) 2012-06-28
US9631022B2 (en) 2017-04-25
US20140127206A1 (en) 2014-05-08
US20100221244A1 (en) 2010-09-02
WO2007133816A3 (en) 2010-11-18
US7943132B2 (en) 2011-05-17
US8409571B2 (en) 2013-04-02
WO2007133816A2 (en) 2007-11-22
US20190119372A1 (en) 2019-04-25
US20170190780A1 (en) 2017-07-06
US20070160611A1 (en) 2007-07-12
MX2008008831A (es) 2009-03-04
CA2636288C (en) 2015-02-24
US8105591B2 (en) 2012-01-31
WO2007143231A3 (en) 2009-08-27
IL219678A0 (en) 2012-06-28
CA2636288A1 (en) 2007-12-13
IL192130A0 (en) 2009-08-03
US9828431B2 (en) 2017-11-28
US20180044426A1 (en) 2018-02-15
AU2007249713A1 (en) 2007-11-22
US20110177086A1 (en) 2011-07-21
US20120207757A1 (en) 2012-08-16
US8968732B2 (en) 2015-03-03
US20110177072A1 (en) 2011-07-21
US20100297125A1 (en) 2010-11-25
EP2594585A1 (en) 2013-05-22
EP2749571A2 (en) 2014-07-02
KR101345586B1 (ko) 2013-12-31
IL192296A0 (en) 2009-08-03
US8637015B2 (en) 2014-01-28
US20140186346A1 (en) 2014-07-03
US8377438B2 (en) 2013-02-19
US20160222123A1 (en) 2016-08-04
AU2007254715A1 (en) 2007-12-13
US8974783B2 (en) 2015-03-10
EP2001906A2 (en) 2008-12-17
US9631021B2 (en) 2017-04-25
KR20080108413A (ko) 2008-12-15
US9334321B2 (en) 2016-05-10
JP2009528264A (ja) 2009-08-06
RU2565391C2 (ru) 2015-10-20
US8105590B2 (en) 2012-01-31
US20130195855A1 (en) 2013-08-01
JP2013047259A (ja) 2013-03-07
US20150132299A1 (en) 2015-05-14
US9834602B2 (en) 2017-12-05
US20120107310A1 (en) 2012-05-03
BRPI0706487A2 (pt) 2011-03-29
US20160222103A1 (en) 2016-08-04
US20170190771A1 (en) 2017-07-06
EP2749571A3 (en) 2014-08-13
US20070160610A1 (en) 2007-07-12
US20130177562A1 (en) 2013-07-11
RU2011137369A (ru) 2013-03-20
US7939068B2 (en) 2011-05-10
US7514077B2 (en) 2009-04-07
CA2633439A1 (en) 2007-11-22
WO2007143231A2 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
US9828431B2 (en) Use of IL-31RA monoclonal antibodies for treating neuronal inflammation
AU2013204175A1 (en) Methods of Treating Pain and Inflammation in Neuronal Tissue Using IL-31 Antagonists

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20090703

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20090703

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120424

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121016